If you're trying to figure out which omega-3 form is actually worth buying, the short answer is: for most healthy adults, an IFOS-certified standard triglyceride (TG) fish oil wins on cost per active milligram, and the bioavailability gap between forms is smaller than the price tag suggests. The forms are not interchangeable on a price-per-bottle basis, but they are roughly interchangeable on a price-per-gram-of-EPA-plus-DHA basis once you do the honest math.
Summary / Quick Answer: which omega-3 form gives the best absorption per dollar?
For general cardiovascular and anti-inflammatory supplementation in a healthy adult, an IFOS-certified standard TG fish oil at roughly 1,000 mg of combined EPA+DHA daily is the form that wins on cost-per-active-milligram.
- Best for the general supplementing adult: standard TG fish oil with IFOS certification. About $0.12 per gram of EPA+DHA at warehouse pricing.
- Best for high-dose triglyceride lowering (3–4 g EPA+DHA daily) where pill burden matters: re-esterified TG (rTG) concentrate. About $0.31 per gram of EPA+DHA.
- Not ideal for cost-sensitive buyers: krill oil. Cost per gram of EPA+DHA runs roughly $2.00 in the typical 300 mg-per-serving format, which is 5 to 15 times the warehouse TG price for a small absorption gain that does not translate into clearly different clinical outcomes.
- Vegan or vegetarian: algal oil is the only viable option. The premium is real but unavoidable.
- Decision shortcut: IFOS certification matters more than form. Rancid oil is the bigger quality risk than form choice.
What bioavailability means for omega-3s
Long-chain omega-3s (EPA and DHA) are fat-soluble. They get incorporated into chylomicrons during fat absorption in the small intestine, then enter circulation via the lymphatic system rather than the portal vein. That route bypasses first-pass hepatic metabolism, which is one reason a single dose can produce measurable changes in plasma phospholipid EPA and DHA within hours.
The absorption barriers are different across forms because the chemistry is different. Native fish oil is a triglyceride: three fatty acid tails on a glycerol backbone. Pancreatic lipase cleaves the outer two positions, and the remaining 2-monoglyceride is taken up by the enterocyte and re-assembled into chylomicrons.
EE forms are a different beast. The fatty acid is bound to an ethanol molecule rather than glycerol. Pancreatic lipase cleaves ethyl esters more slowly than triglycerides, which is the mechanism behind the documented absorption gap. Re-esterified TG products are EE-derived concentrates that have been enzymatically re-attached to a glycerol backbone, restoring TG-like absorption kinetics.
Krill oil carries EPA and DHA on phospholipid backbones rather than triglycerides, which is the biochemical basis for the claim of "better absorption." Algal oil is functionally similar to fish-derived TG oil because the algae (typically Schizochytrium) produce the same triglyceride chemistry that fish accumulate by eating the algae.
The trials in this space measure plasma EPA, DHA, or the omega-3 index (RBC membrane percentage of EPA+DHA), at peak concentration (Cmax) and area-under-the-curve (AUC) after a single dose, or at 4 to 12 weeks of steady-state supplementation. Those proxies are what the comparative bioavailability literature is built on.
The forms compared
Standard triglyceride (TG) fish oil
The native form found in fatty fish and in most warehouse-tier supplements. Brands at this tier include Kirkland Signature, Nordic Naturals standard line, and Carlson's. Typical serving delivers 500–700 mg of combined EPA+DHA per 1,000 mg of total fish oil.
Absorption is the reference point. When trials report "1.0x relative bioavailability," TG is the comparator.
Ethyl ester (EE) fish oil
Most high-EPA concentrates and most prescription omega-3 products are EE. Ethyl ester chemistry is what allows manufacturers to fractionate and concentrate EPA and DHA above the natural ~30% level found in raw fish oil. Prescription Lovaza (omega-3-acid ethyl esters) and Vascepa (icosapent ethyl, EPA-only) are both EE forms.
The widely cited Lawson and Hughes 1988 trial found that EE absorption ran roughly 60% of TG absorption when administered with a low-fat meal, and that the gap narrowed (though did not close) with a high-fat meal. The mechanism is slower pancreatic lipase activity on the ethyl bond.
Re-esterified triglyceride (rTG)
rTG is EE that has been enzymatically reattached to glycerol, restoring the native triglyceride structure on a concentrated EPA+DHA product. The Dyerberg 2010 comparative trial reported that rTG absorption was roughly 124% of natural TG and roughly 173% of EE after 2 weeks of supplementation, measured as percent increase in plasma phospholipid EPA+DHA. Brands at this tier include Nordic Naturals ProOmega and ProEPA lines, Carlson Maximum Omega, and OmegaVia.
Krill oil (phospholipid-bound)
Krill carries omega-3s primarily on phospholipid backbones. The Schuchardt 2011 acute bioavailability trial reported that krill oil and re-esterified TG fish oil produced comparable plasma EPA+DHA AUC over 72 hours, with both modestly outperforming standard EE.
The catch is dose. A typical 1,000 mg krill capsule delivers roughly 100–300 mg of combined EPA+DHA. A typical 1,000 mg fish oil capsule delivers 300–700 mg. To match a fish oil dose, the krill cap count and the cost climb fast. The Maki 2009 trial compared menhaden oil and krill oil at matched EPA+DHA doses over 4 weeks and found broadly comparable changes in the omega-3 index, which undercuts the marketing claim of "less is more."
Algal oil
Vegan-friendly. Most algal products use Schizochytrium-derived DHA, with newer formulations adding EPA. The bioavailability is comparable to fish-derived TG because the chemistry is the same triglyceride structure. The honest tradeoff is that DHA-dominant algal products do not match fish oil on EPA, and EPA+DHA combinations from algae cost roughly $30–50 per month at therapeutic doses.
Form comparison table
| Form | Relative Bioavailability | Typical EPA+DHA per Serving | Approximate Cost per Gram EPA+DHA |
|---|---|---|---|
| Standard TG fish oil (IFOS) | 1.0x (reference) | 500–700 mg | $0.12 |
| Ethyl ester (EE) | 0.60x | 600–1,000 mg | $0.20 |
| Re-esterified TG (rTG) | 1.24x | 1,000–1,400 mg | $0.31 |
| Krill (phospholipid) | 1.0–1.5x | 100–300 mg | $2.00 |
| Algal oil (TG) | ~1.0x | 200–500 mg | $1.20 |
The RCT evidence per form
The 1988 Lawson and Hughes trial remains the foundational TG-vs-EE bioavailability comparison and is the source of the often-cited "EE is about 60% absorbed compared to TG" figure. The trial was small but the effect size has held up in subsequent work.
The Dyerberg 2010 trial is the cleaner head-to-head for the three fish-derived forms: standard TG, EE, and rTG concentrate. After 2 weeks, the relative bioavailability ranking was rTG > TG > EE, and the EE absorption gap was reduced when meals were higher in fat. The absolute increase in plasma phospholipid EPA+DHA at 2 weeks favored rTG by roughly 24% over standard TG, which is a real but modest signal.
The Schuchardt 2011 trial is the most-cited krill-vs-fish-oil acute bioavailability head-to-head. At 72-hour AUC for plasma EPA+DHA, krill ran comparably to rTG fish oil and modestly above EE. The trial did NOT establish krill superiority over standard TG, and it did NOT match the marketing-popular "krill is 1.5x more absorbed than fish oil."
Maki 2009 took the steady-state question. Over 4 weeks of matched 600 mg EPA+DHA dosing, menhaden oil and krill oil produced comparable changes in the omega-3 index. Net: at clinical doses sustained over weeks, the form matters less than the total milligrams delivered.
For the clinical outcome question rather than the bioavailability question, the Bhatt REDUCE-IT trial reported a 25% relative reduction in major adverse cardiovascular events with 4 g/day of prescription icosapent ethyl (EE form of EPA) in patients with high triglycerides and either established CV disease or diabetes plus one additional risk factor. The Manson VITAL trial tested 1 g/day combined EPA+DHA in a generally healthy population and found no significant reduction in the primary composite cardiovascular endpoint, though a secondary signal for MI emerged in subgroup analysis.
The USPSTF 2022 statement on primary cardiovascular prevention gives omega-3 supplementation a Grade C (selective offer, modest benefit), meaning the evidence does not support routine supplementation in average-risk adults for primary CV prevention. The AHA 2017 scientific statement recommends 1 g/day combined EPA+DHA, ideally from 2 servings of fatty fish weekly, for adults with established coronary heart disease.
Actionable takeaway: the standard-of-care framing on omega-3 is narrower than the supplement aisle suggests. For established CHD, AHA endorses 1 g/day. For high triglycerides with CV risk, prescription Vascepa at 4 g/day has trial-level support. For everyone else, the supplement question is about modest adjunctive signal at the margin of normal cardiovascular risk reduction (diet, lipids, blood pressure) that's already doing most of the work.
Cost-vs-bioavailability decision matrix
The math that matters is dollars per gram of actually-absorbed EPA+DHA, not dollars per bottle. Once you adjust for bioavailability and dose per capsule, the cost spread between forms collapses to a much smaller window than the per-bottle prices suggest.
Take the warehouse-tier benchmark. A 200-capsule bottle of Kirkland Signature fish oil at roughly $16 delivers 684 mg EPA+DHA per serving and runs about $0.12 per gram of EPA+DHA at the label dose, dropping further when adjusted for IFOS-verified actual content. Nordic Naturals ProOmega 2000 (rTG concentrate) delivers 1,280 mg EPA+DHA per serving at roughly $0.40 per serving, which lands at about $0.31 per gram of EPA+DHA. Premium, but not 10x premium.
Krill is the cost outlier. A 60-count krill bottle at roughly $36 delivers 300 mg EPA+DHA per serving, landing near $2.00 per gram of EPA+DHA. That's 5 to 15 times the TG price for an absorption advantage that does not survive the steady-state Maki 2009 trial.
When does the rTG premium actually pay off? When the daily target is 2–4 g of EPA+DHA (high triglycerides, prescription-substitute use case where the patient and clinician have agreed on supplemental fish oil rather than Vascepa), the rTG concentrate cuts pill burden roughly in half. That's the legitimate value case for the premium.
When is standard TG fine? For the 1 g/day AHA target in adults without prescription-grade indications, standard TG with IFOS certification covers the goal at a fraction of the cost.
How to choose the right form for your goal
If you're a generally healthy adult supplementing for CV health or anti-inflammatory background support, choose an IFOS-certified standard TG fish oil at 1,000 mg EPA+DHA daily. Kirkland Signature and Nordic Naturals standard line are widely available, IFOS-certified, and deliver the dose at the lowest cost per active milligram.
If you have high triglycerides and have agreed with your clinician on supplemental fish oil at 2–4 g/day rather than Vascepa, choose an rTG concentrate. The reduced pill burden is the real value: roughly 2 to 3 capsules per day instead of 6 to 8.
If you are vegan, vegetarian, or have a religious or sustainability reason to avoid fish-derived oil, choose an algal oil with both EPA and DHA. Accept the higher cost as the price of the dietary constraint, not as an absorption upgrade.
If you have established coronary heart disease, follow the AHA guidance for 1 g/day combined EPA+DHA, ideally from 2 servings per week of fatty fish (salmon, mackerel, sardines, herring) with a supplement only when dietary intake is not feasible.
If you have been told to consider krill specifically: the absorption gain is real but modest, and the cost per active milligram is 5 to 15 times higher. The argument for krill on absorption grounds does not survive the comparative trial data at clinical doses.
Actionable takeaway: form choice matters far less than two other things, total daily EPA+DHA milligrams and third-party oxidation testing. IFOS five-star certification is the floor for both purity and oxidation, not a luxury.
FAQ
Is the EE form a scam? No. EE absorption is roughly 60% of TG on a head-to-head basis, but the gap shrinks when taken with a fatty meal. EE is the form used in prescription Vascepa, which has trial-level cardiovascular outcomes evidence in the REDUCE-IT trial. It is not inferior in clinical effect when dosed to deliver the target EPA+DHA.
Does taking fish oil with food matter? Yes, particularly for EE forms. A meal with at least 10 grams of fat substantially improves EE absorption. For TG and rTG, the effect is smaller but still real.
Are practitioner-channel rTG brands worth the markup? For high-dose use where pill burden matters, yes. For 1 g/day AHA-style supplementation, the cost-per-active-milligram math says no.
Is rancidity a real concern? Yes. Rancid oxidized fish oil is the bigger quality concern than form choice. IFOS five-star certification tests for oxidation markers (TOTOX score) along with heavy metals and PCBs. Capsules that taste fishy or smell off when cut open are likely oxidized and should be discarded.
Can I get enough omega-3 from food? Two weekly servings of fatty fish (salmon, sardines, mackerel, herring) provide roughly the AHA-recommended 1 g/day combined EPA+DHA average, which is the dietary equivalent of the supplement target.
Drug-supplement interaction notes
High-dose fish oil (above 3 g/day combined EPA+DHA) can modestly affect platelet function and bleeding time. Per Drugs.com, notable interactions include warfarin (potentiated anticoagulant effect at high omega-3 doses, INR monitoring recommended), antiplatelet agents like clopidogrel and aspirin (additive bleeding risk at supraphysiologic doses), and antihypertensive medications (mild additive BP-lowering at 3+ g/day). At the AHA-target 1 g/day dose, clinically significant interaction risk is low, but patients on anticoagulation should review supplementation with their prescriber.
Conclusion: the bottom line on omega-3 bioavailability
For the majority of readers supplementing omega-3s, the form question is much smaller than the marketing suggests. Standard TG fish oil with IFOS certification covers the AHA-target dose at the lowest cost per active milligram. rTG concentrates earn their premium when the daily dose climbs into the 2–4 g range and pill burden becomes the limiting factor. EE is not inferior in effect when dosed to the target with a fatty meal, which is why prescription Vascepa works. Krill is overpriced for the absorption gain it delivers and does not separate from TG fish oil at steady state. Algal oil is the right answer for vegans and the wrong answer for everyone else on cost grounds.
The honest comparison is not "premium form versus cheap form." It is "what does my IFOS-certified product cost per gram of EPA+DHA, and am I hitting the daily target the AHA or my clinician recommends." Form drift, oxidation, and underdosing are the three failure modes worth worrying about. Brand prestige is not.
Next steps:
- Review how we evaluate supplements for the testing framework used in this article.
- Read more from Michael Ward, MD MPH on guideline-anchored chronic disease supplementation.
- For dosing, food sources, and the broader role of omega-3s in chronic disease prevention, see the complete guide to omega-3.
Reviewed by Michael Ward, MD MPH, Preventive Medicine, focused on guideline-based chronic disease management.
This article is for informational purposes and not medical advice. Omega-3 supplements can interact with anticoagulant and antiplatelet medications, and high doses may affect bleeding time. Consult a licensed physician before starting any supplement, particularly if you are pregnant, nursing, taking prescription medications, or managing a chronic condition.
Recommended Products
As an Amazon Associate, UsefulVitamins.com earns from qualifying purchases at no extra cost to you. We only recommend products supported by published research or third-party testing.
